InspireMD Reports Record Q3 Revenue with U.S. Launch

InspireMD ( (NSPR) ) has provided an update.

On November 4, 2025, InspireMD reported its financial results for the third quarter of 2025, highlighting a successful initial U.S. commercial launch of its CGuard Prime carotid stent system, which contributed to a record quarterly revenue of $2.5 million, a 39% increase from the previous year. The company completed over 100 carotid procedures in the U.S. and strengthened its leadership team, signaling strong growth and demand for its solutions globally. Despite a net loss of $12.7 million for the quarter, the company is optimistic about its future growth, supported by $58 million in gross proceeds added to its balance sheet in July.

The most recent analyst rating on (NSPR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Spark’s Take on NSPR Stock

According to Spark, TipRanks’ AI Analyst, NSPR is a Neutral.

InspireMD’s overall score is primarily impacted by its financial performance and valuation challenges. Despite positive developments from the earnings call, such as FDA approval and strong market reception, the company’s ongoing profitability and cash flow issues, along with a bearish technical outlook, weigh heavily on the stock’s attractiveness.

To see Spark’s full report on NSPR stock, click here.

More about InspireMD

InspireMD, Inc. is a company focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes. The company utilizes its proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting, providing acute results and durable, stroke-free long-term outcomes. InspireMD’s stock is listed on Nasdaq under the ticker symbol NSPR.

Average Trading Volume: 92,621

Technical Sentiment Signal: Sell

Current Market Cap: $95.54M

See more insights into NSPR stock on TipRanks’ Stock Analysis page.